Plain-English translation of NCT05773859 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new approach to treat advanced ovarian cancer by combining standard chemotherapy and surgery with specialized dendritic cell vaccinations. The vaccine uses your own tumor cells to train your immune system to recognize and fight cancer more effectively. Researchers hope this combination will improve outcomes for patients with advanced epithelial ovarian cancer.
Ovarian cancer remains very difficult to treat, with survival rates that haven't improved much over the past 20 years. This new treatment aims to fill that gap by harnessing your body's immune system to attack the cancer in a way that standard treatments alone cannot achieve.
You likely qualify if…
You likely don't qualify if…
You will receive standard chemotherapy and surgery as usual, with the addition of specialized immune cell vaccinations timed during your treatment. The study involves regular blood tests and monitoring to track how your immune system responds to the vaccine. You'll be closely followed throughout the trial to ensure safety and to measure whether the vaccine helps your body fight the cancer more effectively.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
Netherlands
Phase
Safety & dosing / Early efficacy
Sponsor
Radboud University Medical Center
Enrollment target
~10 participants
Started
March 2023
Primary completion
March 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Sex
Female only
Last updated on clinicaltrials.gov in November 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Bouke Koeneman, MD
Radboud University Medical Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.